COO
Full HouseThe Cooper Companies, Inc. · Healthcare · United States · $11.6B cap · $197.4M/day traded
$62.93 -1.0% · close 11 Nov · scored 12 Nov
Full House: Strong business, sensible price, and the market agrees.
As of 12 Nov 2026, the MoatMap Score for The Cooper Companies, Inc. (COO) is 68/100, ranked against 25,000+ stocks in 38 markets (Quality 56, Value 53, Momentum 55, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT THE COOPER COMPANIES, INC.
Read
The Cooper Companies, Inc. is a global medical device company operating through two distinct segments: CooperVision, a leading manufacturer of contact lenses, and CooperSurgical, a provider of women's healthcare solutions. CooperVision holds a dominant position in specialty contact lenses, while CooperSurgical offers innovative products supporting fertility, diagnostics, and surgical procedures. The company's focus on high-growth, niche medical device markets, backed by strong R&D, provides a resilient business model in the healthcare sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.3B | 3.6B | 3.9B | 4.1B | 7.3% | 4.2B | 4.2B | 4.4B | 3.8% |
| EPS | 1.96 | 1.49 | 1.97 | 1.88 | -1.3% | 2.91 | 2.07 | 2.14 | 6.7% |
| Shares | 197.2M | 198.1M | 199.6M | 195.9M | -0.7% | 190.2M | — | — | — |
| Debt | 2.8B | 2.6B | 2.6B | 2.5B | -3.2% | 2.8B | — | — | — |
| Equity | 7.2B | 7.6B | 8.1B | 8.2B | 4.7% | — | — | — | — |
| Op CF | 692.4M | 607.5M | 709.3M | 796.1M | 4.8% | 1.0B | — | — | — |
| Inv CF | -1.8B | -449.0M | -764.6M | -372.9M | — | — | — | — | — |
| Fin CF | 1.2B | -173.9M | 39.2M | -425.9M | — | — | — | — | — |
No new 52-week low for 8 weeks, 23% above that low, but not back above a rising 50-day average.
The Momentum score still reads 55: it looks back six months, so it has not caught up with this fall.
Calmer than 68% of stocks we rank over the past year (volatility 33% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COO are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| COO | The Cooper Companies, Inc.(you) | $11.6B | 68 |
| AVTR | Avantor, Inc. | $11.7B | 74 |
| SOLV | Solventum Corporation | $14.5B | 66 |
| BAX | Baxter International Inc. | $13.1B | 74 |
| ATR | AptarGroup, Inc. | $8.0B | 65 |
| RGEN | Repligen Corporation | $11.2B | 53 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| MMED | MiniMed Group, Inc. | $5.2B | 60 |
Peer medians: ROE -31.0% · P/E 26.3x · Gross margin 62.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.